Neurocrine/$NBIX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Neurocrine
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
Ticker
$NBIX
Sector
Primary listing
Employees
2,000
Headquarters
Website
Neurocrine Metrics
BasicAdvanced
$13B
27.81
$4.67
0.36
-
Price and volume
Market cap
$13B
Beta
0.36
52-week high
$160.18
52-week low
$84.23
Average daily volume
1.2M
Financial strength
Current ratio
3.393
Quick ratio
1.991
Long term debt to equity
12.766
Total debt to equity
12.766
Profitability
EBITDA (TTM)
666.6
Gross margin (TTM)
62.67%
Net profit margin (TTM)
16.73%
Operating margin (TTM)
22.25%
Effective tax rate (TTM)
32.15%
Revenue per employee (TTM)
$1,430,000
Management effectiveness
Return on assets (TTM)
9.53%
Return on equity (TTM)
16.38%
Valuation
Price to earnings (TTM)
27.807
Price to revenue (TTM)
4.517
Price to book
4
Price to tangible book (TTM)
4
Price to free cash flow (TTM)
17.258
Free cash flow yield (TTM)
5.79%
Free cash flow per share (TTM)
7.525
Growth
Revenue change (TTM)
21.45%
Earnings per share change (TTM)
41.95%
3-year revenue growth (CAGR)
24.32%
10-year revenue growth (CAGR)
64.45%
3-year earnings per share growth (CAGR)
44.12%
10-year earnings per share growth (CAGR)
16.07%
What the Analysts think about Neurocrine
Analyst ratings (Buy, Hold, Sell) for Neurocrine stock.
Neurocrine Financial Performance
Revenues and expenses
Neurocrine Earnings Performance
Company profitability
Neurocrine News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Neurocrine stock?
Neurocrine (NBIX) has a market cap of $13B as of March 12, 2026.
What is the P/E ratio for Neurocrine stock?
The price to earnings (P/E) ratio for Neurocrine (NBIX) stock is 27.81 as of March 12, 2026.
Does Neurocrine stock pay dividends?
No, Neurocrine (NBIX) stock does not pay dividends to its shareholders as of March 12, 2026.
When is the next Neurocrine dividend payment date?
Neurocrine (NBIX) stock does not pay dividends to its shareholders.
What is the beta indicator for Neurocrine?
Neurocrine (NBIX) has a beta rating of 0.36. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.